Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biology of ovarian cancer and trabectedin mechanism of action.

Future oncology (London, England) - 1 Dec 2013

Ray-Coquard Isabelle

Abstract excerpt

More than 50% of patients with ovarian cancer have genetic alterations in the homologous repair pathway. Trabectedin appears to induce damage more readily in tumor cells with defects in the homologous repair system. Moreover, trabectedin inhibits monocyte differentiation into tumor-associated macrophages and inhibits the production of inflammatory mediators such as IL-6. In patients with platinum-sensitive,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dioxoles
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-6

Share to Mutation

Share to Ovarian Neoplasms

Share to Tumor Microenvironment

Source

Identifiers

PMID: 24195525
DOI: 10.2217/fon.13.199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biology of ovarian cancer and trabectedin mechanism of action.PMID 24195525Read ↗

Trabectedin mechanism of action and platinum resistance: molecular rationale.Semantic proximity Read ↗

A Review of Trabectedin (ET-743): A Unique Mechanism of ActionSemantic proximity Read ↗

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional ApproachesSemantic proximity Read ↗

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.Semantic proximity Read ↗

Paclitaxel and Its Evolving Role in the Management of Ovarian CancerSemantic proximity Read ↗

Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromiseSemantic proximity Read ↗

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinSemantic proximity Read ↗

New therapies for ovarian cancer.Semantic proximity Read ↗

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialSemantic proximity Read ↗

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)Semantic proximity Read ↗

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.Semantic proximity Read ↗

[Biologic therapy and epithelial ovarian cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.